Macrophage Therapeutics to Present Data Supporting Potential for Breakthrough with Manocept™ in Immunotherapy
December 12 2014 - 12:20PM
Business Wire
Macrophage Therapeutics, a newly created business unit of
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), is pleased to
present at a conference data generated by independent academic
collaborators that it believes represent a pathway to a potential
major scientific breakthrough in disease therapy, and more
specifically, immunotherapy. Data will be presented to members of
the scientific and investment communities both live in New York
City and via webinar (details below).
Data will be presented that demonstrates that the Manocept™
backbone of tilmanocept, a component of an FDA-approved diagnostic
agent, when attached to selected active therapeutic agents, can
modulate over-active macrophages in clinically meaningful ways. To
date, immunotherapy targeting the innate immune system has been
limited to selectively blocking certain of the chemokines and
cytokines produced by over-active macrophages. As a result of the
high affinity of the Manocept platform compounds to CD206, which is
only found in activated macrophage stages, one can now target the
cell directly and modulate all of the activities of the overactive
cell. This breakthrough has potential implications for radically
new approaches to treatment in a broad array of diseases including
infectious diseases, cancer, cardiovascular, autoimmune and central
nervous system diseases.
Presenting at the webinar will be Frederick O. Cope, Ph.D., who
will provide the technology overview covering the basic aspects of
tilmanocept interactions with macrophages. Dr. Cope will also
present data on the tuberculosis/macrophage relationships and the
tilmanocept/CD206 relationship in the pathology of tuberculosis, as
well as findings in rheumatoid arthritis. These studies have been
generated in collaboration with researchers at The Ohio State
University.
In the area of Kaposi’s sarcoma (KS), Michael McGrath, M.D.,
Ph.D., Professor, University of California, San Francisco, School
of Medicine, will cover work done with tilmanocept in KS, HIV, and
HVC.
Lastly, Steven Grinspoon, M.D., Professor of Medicine at Harvard
Medical School, will discuss the ongoing work with vulnerable
plaque and atherosclerosis and the role of CD206, macrophages and
tilmanocept’s potential interactions in this pathology.
"We are humbled to be entrusted with this scientific
breakthrough that has the potential to help so many patients. Our
priority is to develop additional data in order to advance products
utilizing this technology into clinical testing and then to the
market. We are fortunate that we already have an FDA-approved
indication with this technology as a diagnostic. As a result, we
believe we have addressed many of the key commercialization issues
for the technology and can now focus on the individual therapeutic
applications. We are in the process of creating a Scientific
Advisory Board of leading macrophage-focused immunologists as well
as therapeutic area experts to assist us in prioritization within
major disease categories," said Navidea director Michael M.
Goldberg, M.D., who is leading Navidea’s Macrophage Therapeutics
efforts.
The conference and webinar will be held at 10:00 am (EST) this
coming Monday, December 15th, at 109 West 39th Street, New York, NY
10019.
The conference will also be available streaming online via
webinar at: https://www3.gotomeeting.com/register/264506806, or by
dialing Toll-free: 1 866 952 8437, Access Code: 622 843 441
About Macrophage Therapeutics
Macrophage Therapeutics, a newly created business unit of
Navidea Biopharmaceuticals, Inc., is developing new therapeutics
based on its proprietary CD206 targeting technology platform. This
will represent a new paradigm in the treatment of disease.
Depending on the active agent(s) attached to the Manocept™ backbone
as well as other core molecule permutations, it may be possible to
approach immunotherapy in a completely novel manner. This approach
has the potential to provide for management and modification of
diseases that include the immediate involvement of macrophages, the
biological products of macrophages, or the effective impact of
macrophages or their progenitor and/or daughter elements. Thus,
Macrophage Therapeutics’ Manocept platform is designed to
specifically address a key element, macrophage interactions, in the
natural progression of clinically significant diseases that impact
the lives of patients around the globe.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics and radiopharmaceutical
agents. For more information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
Macrophage TherapeuticsMichael M. Goldberg, M.D.
201-608-5218orNavidea BiopharmaceuticalsBrent Larson,
614-822-2330Executive VP & CFO
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024